<DOC>
	<DOCNO>NCT00919282</DOCNO>
	<brief_summary>The purpose study examine efficacy safety drug combination GFF patient advance pancreatic cancer ( APC ) .</brief_summary>
	<brief_title>Gemcitabine ( GFF ) Patients With Pancreatic Cancer</brief_title>
	<detailed_description>This open-label , multi center phase II study conduct investigate efficacy safety combination 5-Fluorouracil ( 5-FU ) /folinic acid ( FA ) plus gemcitabine ( GFF ) patient ( pt ) advance pancreatic cancer ( APC ) . We consequently start study complete phase I trial accomplish CONKO- study group .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>histological prove pancreatic cancer inoperable disease inform consent adequate bone marrow reserve 18 year brain metastasis lactate woman life expectancy 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>combination</keyword>
</DOC>